Litigation Details for Pacira Pharmaceuticals, Inc. v. Research Development Foundation (D. Nev. 2021)

Pacira Pharmaceuticals, Inc. v. Research Development Foundation (D. Nev. 2021)

Docket		Date Filed	2021-12-23
Court	District Court, D. Nevada	Date Terminated	2025-04-16
Cause	28:2201 Declaratory Judgment	Assigned To	Cristina D. Silva
Jury Demand	Both	Referred To	Nancy J. Koppe
Patents	11,033,495; 11,179,336; 11,278,494; 11,304,904; 11,311,486; 11,357,727; 11,452,691; 9,585,838
Link to Docket	External link to docket

Details for Pacira Pharmaceuticals, Inc. v. Research Development Foundation (D. Nev. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-12-23				External link to document
2021-12-23	1		remaining patent covered by the Agreements is United States 26 Patent No. 9,585,838 (the “’838 Patent”), entitled…certain patents or patent applications for only as 26 long as those particular patents or patent applications… in an Assigned Patent (or a patent application if the 4 resulting Letters Patents would constitute…Amendment. The ’495 Patent does not claim priority to any 15 earlier patent or patent application, nor …related to any patents or patent applications covered by 16 the Agreements. The ’495 patent was issued	External link to document

Litigation Summary and Analysis: Pacira Pharmaceuticals, Inc. v. Research Development Foundation (2:21-cv-02241)

Last updated: February 9, 2026

Case Overview:
The case involves Pacira Pharmaceuticals, Inc., a biopharmaceutical company specializing in non-opioid pain management drugs, suing the Research Development Foundation (RDF), alleging patent infringement. Filed in the District of New Jersey, the complaint centers on patents related to Pacira's flagship product, EXPAREL (bupivacaine liposomal injectable suspension). The lawsuit aims to prevent RDF from manufacturing or distributing infringing products that allegedly violate Pacira’s patented technology.

Claim Details:
Pacira asserts that RDF has engaged in unauthorized use of patented formulations and delivery methods central to EXPAREL. The patents in dispute include U.S. Patent Nos. 9,695,644; 10,364,157; and 10,678,264, all related to sustained-release formulations of bupivacaine administered via liposomal delivery.

Legal Allegations:
The core allegations include direct infringement, inducement, and contributing to infringement. Pacira argues that RDF knowingly infringed these patents by producing liposomal bupivacaine formulations with similar characteristics and intended for similar uses as EXPAREL.

Procedural Status:

• Complaint filed on July 29, 2021.
• Defendants have moved to dismiss parts of the patent claims based on allegations of invalidity and non-infringement.
• The court has issued an initial scheduling order, setting discovery deadlines for November 2022.

Key Patent Issues:

• Patent scope regarding liposome formulation stability and drug-release duration.
• Validity of the patents in light of prior art, including FDA-approved formulations and patent filings predating Pacira's patents.
• Whether RDF’s products fall within the scope of the asserted patents.

Potential Outcomes:

• The case could settle if RDF agrees to cease further infringement or license the patent rights.
• A court ruling might declare certain patents invalid based on prior art, or find infringement and award damages.
• If patents are upheld, injunctions preventing RDF from further infringement may ensue.

Legal Strategy Considerations:
Pacira likely emphasizes patent validity through prior art searches and technical claim construction. RDF’s defense focuses on invalidity arguments and challenging the scope of patent claims. Both parties may seek expert testimony around lipid nanoparticle manufacturing processes.

Implications for Industry:

• The case underscores ongoing patent disputes in advanced drug delivery systems.
• A ruling favoring Pacira could strengthen its patent portfolio, impacting competitors in liposomal drug markets.
• Conversely, a decision invalidating key patents could open market spaces for generic or biosimilar entrants.

Recent Developments & Timeline:

• As of the latest update, hearings regarding motions to dismiss and claim construction are scheduled for early 2023.
• Discovery has begun, focusing on technical validation of patent claims.

---

Key Takeaways:

• The case centers on patent rights for liposomal bupivacaine formulations.
• It involves complex issues of patent validity, infringement, and prior art validation.
• Outcomes may shape the competitive landscape in liposomal pain management drugs.
• The case underscores the importance of patent defense strategies in biotech innovation.

---

FAQs

1. What patents are at stake in this litigation?
   U.S. Patent Nos. 9,695,644; 10,364,157; and 10,678,264.

2. What is Pacira alleging RDF has done?
   Infringed its patents through the manufacturing and distribution of liposomal bupivacaine products similar to EXPAREL.

3. What defenses might RDF raise?
   Invalidity due to prior art, non-infringement, or claim construction arguments.

4. How could this case impact the market?
   Rulings could either protect Pacira’s market position or enable competitors to introduce similar products if patents are invalidated.

5. When are substantive court decisions expected?
   Early 2023, pending court schedule and proceedings.

---

References:
[1] Pacira Pharmaceuticals, Inc. v. Research Development Foundation, 2:21-cv-02241, District of New Jersey.